AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 94 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $92,351 | +64481.1% | 318,451 | 0.0% | 0.00% | -100.0% |
Q4 2022 | $143 | -99.9% | 318,451 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $168,000 | -48.3% | 318,451 | -50.5% | 0.00% | 0.0% |
Q2 2022 | $325,000 | -73.0% | 642,835 | +22.9% | 0.00% | -66.7% |
Q1 2022 | $1,203,000 | -39.2% | 523,142 | +25.7% | 0.00% | -50.0% |
Q4 2021 | $1,977,000 | -6.9% | 416,174 | +55.8% | 0.01% | -14.3% |
Q3 2021 | $2,123,000 | +8.2% | 267,066 | -5.3% | 0.01% | 0.0% |
Q2 2021 | $1,963,000 | +67.8% | 282,068 | +90.9% | 0.01% | +40.0% |
Q1 2021 | $1,170,000 | -7.6% | 147,790 | -8.1% | 0.01% | -16.7% |
Q4 2020 | $1,266,000 | +47.2% | 160,885 | +32.6% | 0.01% | +20.0% |
Q3 2020 | $860,000 | -72.1% | 121,344 | -63.5% | 0.01% | -75.0% |
Q2 2020 | $3,078,000 | +3040.8% | 332,731 | +2498.9% | 0.02% | +1900.0% |
Q3 2019 | $98,000 | -93.1% | 12,803 | -93.8% | 0.00% | -90.9% |
Q2 2019 | $1,423,000 | +88.0% | 207,794 | +121.0% | 0.01% | +57.1% |
Q1 2019 | $757,000 | – | 94,027 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Yu Fan | 112,044 | $258,000 | 3.49% |
Aisling Capital Management LP | 1,691,151 | $3,890,000 | 2.10% |
Sio Capital Management, LLC | 871,101 | $2,004,000 | 0.66% |
Bain Capital Life Sciences Investors, LLC | 2,847,689 | $6,550,000 | 0.64% |
Samsara BioCapital, LLC | 883,720 | $2,033,000 | 0.51% |
Ghost Tree Capital, LLC | 686,599 | $1,579,000 | 0.34% |
Nantahala Capital Management | 3,200,593 | $7,361,000 | 0.33% |
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $565,000 | 0.29% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 4,059,894 | $9,338,000 | 0.28% |
Lion Point Capital, LP | 300,000 | $690,000 | 0.16% |